376 related articles for article (PubMed ID: 26920060)
1. Concurrent targeting Akt and sphingosine kinase 1 by A-674563 in acute myeloid leukemia cells.
Xu L; Zhang Y; Gao M; Wang G; Fu Y
Biochem Biophys Res Commun; 2016 Apr; 472(4):662-8. PubMed ID: 26920060
[TBL] [Abstract][Full Text] [Related]
2. SphK1 inhibitor II (SKI-II) inhibits acute myelogenous leukemia cell growth in vitro and in vivo.
Yang L; Weng W; Sun ZX; Fu XJ; Ma J; Zhuang WF
Biochem Biophys Res Commun; 2015 May; 460(4):903-8. PubMed ID: 25824043
[TBL] [Abstract][Full Text] [Related]
3. Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.
Powell JA; Lewis AC; Zhu W; Toubia J; Pitman MR; Wallington-Beddoe CT; Moretti PA; Iarossi D; Samaraweera SE; Cummings N; Ramshaw HS; Thomas D; Wei AH; Lopez AF; D'Andrea RJ; Lewis ID; Pitson SM
Blood; 2017 Feb; 129(6):771-782. PubMed ID: 27956387
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of WYE-687, a mTOR kinase inhibitor, as a potential anti-acute myeloid leukemia agent.
Cheng F; Wang L; Shen Y; Xia J; Chen H; Jiang Y; Lu M
Biochem Biophys Res Commun; 2016 Feb; 470(2):324-330. PubMed ID: 26792718
[TBL] [Abstract][Full Text] [Related]
5. Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth.
Qin L; Tian Y; Yu Z; Shi D; Wang J; Zhang C; Peng R; Chen X; Liu C; Chen Y; Huang W; Deng W
Oncotarget; 2016 Jan; 7(2):1395-407. PubMed ID: 26593251
[TBL] [Abstract][Full Text] [Related]
6. Pre-clinical assessment of A-674563 as an anti-melanoma agent.
Zou Y; Fan G; Wang X
Biochem Biophys Res Commun; 2016 Aug; 477(1):1-8. PubMed ID: 26970307
[TBL] [Abstract][Full Text] [Related]
7. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia.
Paugh SW; Paugh BS; Rahmani M; Kapitonov D; Almenara JA; Kordula T; Milstien S; Adams JK; Zipkin RE; Grant S; Spiegel S
Blood; 2008 Aug; 112(4):1382-91. PubMed ID: 18511810
[TBL] [Abstract][Full Text] [Related]
8. AT7867 Inhibits Human Colorectal Cancer Cells via AKT-Dependent and AKT-Independent Mechanisms.
Zhang S; Deng Z; Yao C; Huang P; Zhang Y; Cao S; Li X
PLoS One; 2017; 12(1):e0169585. PubMed ID: 28081222
[TBL] [Abstract][Full Text] [Related]
9. Hyperforin inhibits Akt1 kinase activity and promotes caspase-mediated apoptosis involving Bad and Noxa activation in human myeloid tumor cells.
Merhi F; Tang R; Piedfer M; Mathieu J; Bombarda I; Zaher M; Kolb JP; Billard C; Bauvois B
PLoS One; 2011; 6(10):e25963. PubMed ID: 21998731
[TBL] [Abstract][Full Text] [Related]
10. Apatinib exhibits cytotoxicity toward leukemia cells by targeting VEGFR2-mediated prosurvival signaling and angiogenesis.
Deng M; Zha J; Zhao H; Jia X; Shi Y; Li Z; Fu G; Yu L; Fang Z; Xu B
Exp Cell Res; 2020 May; 390(1):111934. PubMed ID: 32126236
[TBL] [Abstract][Full Text] [Related]
11. K6PC-5, a novel sphingosine kinase 1 (SphK1) activator, alleviates dexamethasone-induced damages to osteoblasts through activating SphK1-Akt signaling.
Ji F; Mao L; Liu Y; Cao X; Xie Y; Wang S; Fei H
Biochem Biophys Res Commun; 2015 Mar; 458(3):568-575. PubMed ID: 25680461
[TBL] [Abstract][Full Text] [Related]
12. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
[TBL] [Abstract][Full Text] [Related]
13. OSU-A9, an indole-3-carbinol derivative, induces cytotoxicity in acute myeloid leukemia through reactive oxygen species-mediated apoptosis.
Bai LY; Weng JR; Chiu CF; Wu CY; Yeh SP; Sargeant AM; Lin PH; Liao YM
Biochem Pharmacol; 2013 Nov; 86(10):1430-40. PubMed ID: 24041743
[TBL] [Abstract][Full Text] [Related]
14. Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors.
Heo SK; Noh EK; Gwon GD; Kim JY; Jo JC; Choi Y; Koh S; Baek JH; Min YJ; Kim H
Eur J Pharmacol; 2016 Oct; 789():280-290. PubMed ID: 27477352
[TBL] [Abstract][Full Text] [Related]
15. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
[TBL] [Abstract][Full Text] [Related]
16. Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth.
Zhou J; Chen J; Yu H
Biochem Biophys Res Commun; 2018 Mar; 497(2):535-542. PubMed ID: 29428730
[TBL] [Abstract][Full Text] [Related]
17. Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma.
Li W; Li J; Wang Y; Zhang K; Li N; Tian Z; Ni B; Wang H; Ruan Z
Oncotarget; 2016 Dec; 7(49):80586-80598. PubMed ID: 27811359
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia.
Zeng Z; Samudio IJ; Zhang W; Estrov Z; Pelicano H; Harris D; Frolova O; Hail N; Chen W; Kornblau SM; Huang P; Lu Y; Mills GB; Andreeff M; Konopleva M
Cancer Res; 2006 Apr; 66(7):3737-46. PubMed ID: 16585200
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
[TBL] [Abstract][Full Text] [Related]
20. T315 Decreases Acute Myeloid Leukemia Cell Viability through a Combination of Apoptosis Induction and Autophagic Cell Death.
Chiu CF; Weng JR; Jadhav A; Wu CY; Sargeant AM; Bai LY
Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27537872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
